Madrigal Pharmaceuticals, Inc.
MDGL
NASDAQ·Healthcare·Biotechnology·Mkt cap $12.5B
$541.08
▼ -0.28%
P/E
-41.98
Mkt Cap
$12.5B
52-Wk Range
$393.61–$615.00
52-Week Range
$393.61 - $615.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 19.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Liver-directed selective mechanism of action minimizing systemic thyroid hormone effects
- Strategic partnership with Hoffmann-La Roche providing development and commercialization support
- Advanced clinical stage (Phase III) with lead candidate addressing large unmet NASH market need
- Focused pipeline strategy reducing development complexity and capital requirements
Bear Case
1 risk
- Low volatility (beta -1.0).
Growth
Moderate growth ahead
Phase III clinical trial success for resmetirom in NASH treatment
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Strong
+11.1% over 3m
Quality
Excellent
High-growth business (149% revenue growth, 91% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying MDGL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
JUL 30, 2026
Reported EPS of -$1.99 vs -$2.68 consensus (+25.8% surprise). Revenue of $364.3M vs $352.1M expected (+3.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+25.8%
Revenue trend · last 8Q
—
—
—
—
+362%
+211%
+127%
+71%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$62.2M
$103.3M
$137.3M
$212.8M
$287.3M
$321.1M
$311.3M
$364.3M
Margins · last 8Q
Gross
89.0%
Operating
-15.5%
Profit
-15.9%
Wall Street consensus
11 analysts · 91% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
91%
Hold
9%
Sell
0%
Median Price Target
—
Latest: Wolfe Research · Aug 4, 2026
vs Industry
How MDGL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related